You are here
Ascendis Pharma A/S Announces Presentations on Technology and Rare Disease Endocrinology Pipeline at September Conferences
COPENHAGEN, Denmark, Sept. 06, 2018 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND), a biopharmaceutical company that utilizes its innovative TransCon™ technology to address significant unmet medical needs, today announced upcoming presentations related to its technology platform and rare endocrine disease pipeline.
Six poster presentations will take place at the upcoming conferences, including the Ninth International Congress of the Growth Hormone Research (GRS) and Insulin-like Growth Factors (IGF) Societies from September 14-17, 2018; the European Society for Paediatric Endocrinology (ESPE) annual meeting from September 27-29, 2018; and the American Society for Bone and Mineral Research (ASBMR) annual meeting from September 28-October 1, 2018. Additionally, the company will make an oral presentation about its TransCon technology platform at the Boulder Peptide Symposium taking place September 24-27.
“These presentations highlight our ability to design product candidates that address unmet medical needs, using our innovative TransCon technology platform,” said Jan Mikkelsen, Ascendis Pharma’s President and CEO. “As our endocrinology pipeline advances and matures in the clinic, we continue to build awareness among the scientific and medical communities, reflecting our strong commitment to patients and science.”
Details about the presentations are listed below. Following the sessions, the presentations will be available on the company’s website under Selected Publications in the Pipeline section.
GRS & IGF Societies (Seattle): TransCon Growth Hormone
|Meeting Unmet Needs: The Sustained-Release of Protein and Peptide Drugs|
Poster #15G (Late-breaking Abstract #231)
|Saturday, September 15|
11:30 a.m. – 1:30 p.m.
|Baseline Demographics of the TransCon Growth Hormone Phase 3 heiGHt Trial |
Poster #18 (Abstract #64)
|Sunday, September 16|
11:30 a.m. – 1:30 p.m.
Boulder Peptide Symposium (Denver): TransCon Technology
|TransCon Technology for Sustained Delivery of Proteins, Peptides, and Small Molecules|
|Wednesday, September 26|
9:00 – 9:40 a.m.
ESPE (Athens, Greece): TransCon Growth Hormone
|The Rationale and Design of TransCon GH|
|Friday, September 28|
1:15 – 2:15 p.m.
|Baseline Demographics of the TransCon Growth Hormone Phase 3 heiGHt Trial|
|Friday, September 28|
1:15 – 2:15 p.m.
ASBMR (Montreal): TransCon PTH
|The Effect of TransCon PTH on Bone Turnover in a Phase 1 Trial|
|Friday, September 30|
12:30 – 2:30 p.m.
|The Design and Results of a Phase 1 TransCon PTH Trial in Healthy Volunteers|
|Monday, October 1|
12:00 – 2:00 p.m.
About Ascendis Pharma A/S
Ascendis Pharma is applying its innovative platform technology to build a leading, fully integrated biopharma company focused on making a meaningful difference in patients’ lives. Guided by its core values of patients, science and passion, the company utilizes its TransCon™ technology to create new and potentially best-in-class therapies.
Ascendis Pharma currently has a pipeline of three wholly-owned, independent rare disease endocrinology product candidates in clinical development. Additionally, Ascendis Pharma has multi-product collaborations with Sanofi in diabetes and Genentech in the field of ophthalmology and continues to expand into additional therapeutic areas for both internal and external development.
Ascendis is headquartered in Copenhagen, Denmark, with offices in Heidelberg, Germany and Palo Alto, California.
For more information, please visit www.ascendispharma.com.
This press release contains forward-looking statements that involve substantial risks and uncertainties. All statements, other than statements of historical facts, included in this press release regarding our future operations, plans and objectives of management are forward-looking statements. Examples of such statements include, but are not limited to, statements relating to (i) our ability to apply our platform technology to build a leading, fully integrated biopharma company, (ii) our expectations regarding our ability to create potentially best-in-class therapies and (iii) our product pipeline. We may not actually achieve the plans, carry out the intentions or meet the expectations or projections disclosed in the forward-looking statements and you should not place undue reliance on these forward-looking statements. Actual results or events could differ materially from the plans, intentions, expectations and projections disclosed in the forward-looking statements. Various important factors could cause actual results or events to differ materially from the forward-looking statements that we make, including the following: unforeseen safety or efficacy results in our TransCon hGH, TransCon PTH and TransCon CNP or other development programs; unforeseen expenses related to the development of TransCon hGH, TransCon PTH and TransCon CNP or other development programs, general and administrative expenses, other research and development expenses and our business generally; delays in the development of TransCon hGH, TransCon PTH and TransCon CNP or other development programs related to manufacturing, regulatory requirements, speed of patient recruitment or other unforeseen delays; dependence on third party manufacturers to supply study drug for planned clinical studies; and our ability to obtain additional funding, if needed, to support our business activities. For a further description of the risks and uncertainties that could cause actual results to differ from those expressed in these forward-looking statements, as well as risks relating to our business in general, see our current and future reports filed with, or submitted to, the U.S. Securities and Exchange Commission (SEC), including our Annual Report on Form 20-F for the year ended December 31, 2017, which we filed with the SEC on March 28, 2018. Forward-looking statements do not reflect the potential impact of any future in-licensing, collaborations, acquisitions, mergers, dispositions, joint ventures, or investments we may enter into or make. We do not assume any obligation to update any forward-looking statements, except as required by law.
Ascendis, Ascendis Pharma, the Ascendis Pharma logo, the company logo and TransCon are trademarks owned by the Ascendis Pharma group.© September 2018 Ascendis Pharma A/S.
CONTACT: Internal contact: Scott T. Smith Chief Financial Officer (650) 352-8389 email@example.com Media contact: Ami Knoefler Head of Global Communications (650) 739-9952 firstname.lastname@example.org Investor contact: Patti Bank Westwicke Partners (415) 513-1284 email@example.com